Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) CFO Charles N. York II sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $20.05, for a total transaction of $200,500.00. Following the completion of the sale, the chief financial officer now directly owns 321,365 shares in the company, valued at $6,443,368.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Day One Biopharmaceuticals Trading Up 15.6 %
DAWN stock traded up $3.19 during midday trading on Friday, reaching $23.64. 932,724 shares of the company’s stock traded hands, compared to its average volume of 842,862. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $5.44 and a fifty-two week high of $28.70. The business has a 50-day moving average price of $15.39 and a two-hundred day moving average price of $12.69.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.09). On average, analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2 EPS for the current year.
Wall Street Analyst Weigh In
Institutional Trading of Day One Biopharmaceuticals
A number of hedge funds have recently made changes to their positions in DAWN. New York State Common Retirement Fund purchased a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $137,000. Canaan Partners XI LLC purchased a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $162,832,000. Northern Trust Corp raised its stake in shares of Day One Biopharmaceuticals by 5.7% during the fourth quarter. Northern Trust Corp now owns 103,677 shares of the company’s stock valued at $1,747,000 after purchasing an additional 5,578 shares during the period. ProShare Advisors LLC purchased a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $188,000. Finally, Alps Advisors Inc. purchased a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $1,208,000. Hedge funds and other institutional investors own 79.02% of the company’s stock.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.